Ibogaine for the treatment of Parkinson's disease: A case report
Journal of Psychedelic Studies January 6, 2026 Tobias Erny, Elba Yatziri Cano Montenegro, Joern Barth et al.
Abstract Background and Aims Parkinson's disease (PD) significantly impairs quality of life, and current treatments do not halt dopaminergic neurodegeneration. Evidence suggests that ibogaine, a naturally occurring indole alkaloid, may stimulate glial cell line-derived neurotrophic factor (GDNF) expression and affect dopamine transporter (DAT) function. This case study reports the effects of...